Audit 314943

FY End
2023-12-31
Total Expended
$3.26M
Findings
0
Programs
4
Year: 2023 Accepted: 2024-07-11
Auditor: Leaf & Cole LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.310 Trans-Nih Research Support $534,515 Yes 0
93.855 Allergy, Immunology and Transplantation Research $54,411 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $19,659 Yes 0
93.837 Cardiovascular Diseases Research $2,836 Yes 0

Contacts

Name Title Type
CSLYY6VAHXX7 Martha Llona Auditee
8582497407 Jill Branch Auditor
No contacts on file

Notes to SEFA

Title: Note 1 - Basis of Presentation: Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following, as applicable, either the cost principles contained in OMB Circular A-122, Cost Principles for Non-Profit Organizations or the cost principles contained in Uniform Guidance wherein certain types of expenditures are not allowable or are limited as to reimbursement. Pass-through entity identifying numbers are presented where available. De Minimis Rate Used: N Rate Explanation: The California Medical Innovations Institute has elected not to use the 10-percent de minimis indirect cost rate as allowed under Uniform Guidance. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of the California Medical Innovations Institute under programs of the federal government for the year ended December 31, 2023. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the California Medical Innovations Institute, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the California Medical Innovations Institute.
Title: Note 2 - Summary of Significant Accounting Policies: Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following, as applicable, either the cost principles contained in OMB Circular A-122, Cost Principles for Non-Profit Organizations or the cost principles contained in Uniform Guidance wherein certain types of expenditures are not allowable or are limited as to reimbursement. Pass-through entity identifying numbers are presented where available. De Minimis Rate Used: N Rate Explanation: The California Medical Innovations Institute has elected not to use the 10-percent de minimis indirect cost rate as allowed under Uniform Guidance. Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following, as applicable, either the cost principles contained in OMB Circular A-122, Cost Principles for Non-Profit Organizations or the cost principles contained in Uniform Guidance wherein certain types of expenditures are not allowable or are limited as to reimbursement. Pass-through entity identifying numbers are presented where available. The California Medical Innovations Institute has elected not to use the 10-percent de minimis indirect cost rate as allowed under Uniform Guidance.